September is Blood Cancer Awareness Month. We stand with everyone living with blood cancer — this month and every day.

Publications & Presentations

Advancing scientific understanding from research to real-world evidence.
Every study contributes to a deeper understanding of blood cancer and the potential for new treatment approaches. Through clinical trials, real-world evidence, investigator-sponsored research, and scientific collaboration, Geron is committed to generating evidence that may help advance science, inform clinical practice, and improve outcomes for people living with blood cancer.

Explore our scientific publications and presentations:

This page may contain non-exhaustive scientific information about post-hoc, exploratory, subgroup analyses, or uses that have not yet been approved by regulatory authorities. The information is provided for educational and scientific exchange purposes only, and does not suggest products should be used in a manner not consistent with their respective label approved by the regulatory authorities, which may differ by geography. Any publication reflects the state of knowledge at the time it was published. The information is not medical advice and cannot replace the independent medical judgement of a healthcare professional.

Journal articles

Increased duration of time without transfusion reliance with imetelstat vs placebo in the phase 3 IMerge trial

Blood Neoplasia

April 16, 2026
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Association between treatment-emergent cytopenias and clinical responses to imetelstat in lower-risk myelodysplastic syndromes

Blood Cancer Journal

April 7, 2026
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Clinical outcomes and safety in patients with lower-risk myelodysplastic syndromes treated with imetelstat: Substudy of the phase 3 IMerge trial

British Journal of Haematology

February 1, 2026
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study

Haematologica

January 22, 2026
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat

Nature Leukemia

January 12, 2026
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS

Blood Cancer Journal

December 31, 2025
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

No Effect of Immunogenicity on Pharmacokinetics, Efficacy, and Safety of the Oligonucleotide Telomerase Inhibitor Imetelstat in Lower-Risk Myelodysplastic Syndromes

Clinical and Translational Science

December 14, 2025
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Plain language summary of IMerge, a Phase 3 studyof imetelstat versus placebo in people with lower-risk myelodysplastic syndromes and anemia

Future Oncology

October 12, 2025
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Transfusion Independence Corresponds With Survival in Patients With Lower-Risk Myelodysplastic Syndrome: Real-World Evidence From United States Insurance Claims

Clinical Lymphoma, Myeloma and Leukemia

October 1, 2025
Lower-risk Myelodysplastic Syndromes (LR-MDS)Real-World Data

Imetelstat: A First-in-Class Telomerase Inhibitor for the Treatment of Patients With Lower-Risk Myelodysplastic Syndromes and Anemia

Online First

June 25, 2025
Lower-risk Myelodysplastic Syndromes (LR-MDS)Review

Low Proarrhythmic Risk of Imetelstat, a Novel Oligonucleotide Telomerase Inhibitor: A Translational Analysis

Clinical and Translational Science

January 21, 2025
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Imetelstat, a novel, first-in-class telomerase inhibitor: Mechanism of action, clinical, and translational science

Clinical and Translational Science

November 21, 2024
Review

Conference presentations

Correlation Analyses of Imetelstat Exposure with Pharmacodynamic Effect, Efficacy and Safety in a Phase 2 Study in Patients with Higher-risk Myelofibrosis Refractory to Janus Kinase Inhibitor Identified an Optimal Dosing Regimen for Phase 3 Study

ASH 2020

December 5, 2020
Myelofibrosis (MF)Clinical Data

Imetelstat Treatment Results in Clinical Benefits, Including Improved Overall Survival, in Patients with Higher-Risk Triple Negative Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitors (JAKi)

ASH 2020

December 5, 2020
Myelofibrosis (MF)Clinical Data

Treatment with Imetelstat Improves Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in Patients with Relapsed or Refractory Higher-Risk Myelofibrosis

ASH 2020

December 5, 2020
Myelofibrosis (MF)Clinical Data

A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK) Inhibitor

ASH 2020

December 5, 2020
Myelofibrosis (MF)Clinical Data

Imetelstat Inhibits Telomerase and Prevents Propagation of ADAR1-Activated Myeloproliferative Neoplasm and Leukemia Stem Cells

ASH 2020

December 5, 2020
Preclinical Data

Treatment with Imetelstat Provides Durable Transfusion Independence (TI) in Heavily Transfused Non-Del(5Q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs)

EHA 2020

June 12, 2020
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Favorable Overall Survival with Imetelstat Treatment Correlates with Other Clinical Benefits in Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor

EHA 2020

June 12, 2020
Myelofibrosis (MF)Clinical Data

Imetelstat Treatment Results in Clinical Benefits, Including Improved Overall Survival, in Patients with Higher-Risk Triple-Negative Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitors (JAKi)

EHA 2020

June 12, 2020
Myelofibrosis (MF)Clinical Data

Telomerase Activity, Telomere Length and hTERT Expression Correlate with Clinical Outcomes in Higher-Risk Myelofibrosis (MF) Relapsed/Refractory (R/R) to Janus Kinase Inhibitor Treated with Imetelstat

EHA 2020

June 12, 2020
Myelofibrosis (MF)Clinical Data

IMerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

ASH 2019

December 5, 2019
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Combination Treatment with Imetelstat, a Telomerase Inhibitor, and Ruxolitinib Depletes Myelofibrosis Hematopoietic Stem Cells and Progenitor Cells

ASH 2019

December 5, 2019
Myelofibrosis (MF)Preclinical Data

Treatment with Imetelstat Provides Durable Transfusion Independence in Heavily Transfused Non-del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agents

EHA 2019

June 12, 2019
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data